Careers  |  Sign In  |  Register

Latest Additions

[case_player][/case_player] The National Cancer Institute has developed a cloud-based infrastructure, the Cancer Research Data Commons, which allows cancer researchers to access, share, and analyze data from a centralized location, without the need to download or store vast stores of data....

PD-1 Immune Therapies May Leave Gap in Treatment of RCC

Dr. Braun on Unanswered Questions With PD-1 Blockade in Advanced RCC

David A. Braun, MD, PhD, physician at Dana-Farber Cancer Institute and instructor of medicine at Harvard Medical School, explains that while PD-1 blockade and immune therapies have been transformative for the treatment of renal cell carcinoma (RCC), not all patients respond to these standards of care. Kidney...

Prognosis of Patients with Central Nervous System Metastases from Melanoma

Dr. Glitza Olivia on the Prognosis of Melanoma Brain Metastases

Isabella C. Glitza Oliva, MD, PhD, MS, assistant professor in the Department of Melanoma Medical Oncology, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses central nervous system (CNS) metastases from melanoma. Of all solid tumors, melanoma is most likely to...

A Look at Certain Current Treatment Options for NSCLC Patients Lacking Driver Mutations

Navigating New Immune-Based Combinations in Advanced NSCLC

Joshua K. Sabari, MD, assistant professor, Department of Medicine, NYU Langone Health’s Perlmutter Cancer Center, discusses the limited treatment options for non-small cell lung cancer (NSCLC) patients without known driver mutations. Dr. Sabari recommends pembrolizumab for patients with high PDL-1, while a...
Gal Markel, MD, PhD, chief scientist and senior oncologist at Sheba Medical Center, discusses the use of fecal microbiota transplant (FMT) for melanoma patients nonresponsive to PD-1 inhibition. FMT patients are reintroduced to PD-1 inhibitors post-transplant. The initial cohort showed 30% of patients...
Chung-Han Lee, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, reports recent findings from a study using pembrolizumab and lenvatinib as a second-line treatment for clear cell renal cell carcinoma (ccRCC). Dr. Lee states that patients in the trial exhibited a 55% objective response rate...
Suresh Ramalingam, MD, FASCO, deputy director, Winship Cancer Institute of Emory University, addresses autoimmune toxicities associated with combination immune therapies as in the CheckMate-227 trial for non-small cell lung cancer (NSCLC). Dr. Ramalingam asserts that most of these salient toxicities occur...
[case_player][/case_player] A research team at UCSF has developed an antiviral aerosol spray, dubbed AeroNabs, that they report has the ability to ward off coronoavirus infection by blocking the ACE2 receptor pathway. The protective molecule is synthesized in a lab by imprinting the genetic blueprints of...
Joshua K. Sabari, MD, assistant professor in the Department of Medicine at NYU Langone Health’s Perlmutter Cancer Center, addresses the need for additional predictive biomarkers for non-small cell lung cancer (NSCLC) patients with no known driver mutation. Dr. Sabari says, to date, PD-L1 is the only...
Rana R. McKay, MD, assistant professor of medicine and medical oncologist at the University of California San Diego, discusses the PDIGREE study design for the treatment of renal cell carcinoma (RCC). Patients initially receive nivolumab plus ipilimumab. Those patients who exhibit a complete response...